Leicester General Hospital
Leicester LE5 4PW
10 studies enrolling now · 31 studies all time
What they study most
Active Refractory Rheumatoid Arthritis, Advanced Solid Tumor, Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC), Ankylosing Spondylitis, Cardiovascular Disease, Cardiovascular Risk, Chronic Kidney Disease, Cytomegalovirus (CMV) Infection, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diffuse Large B Cell Lymphoma
Studies at this site
- A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases — Recruiting now
- A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight — Recruiting now
- A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS) — Recruiting now
- A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis — Recruiting now
- Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease — Recruiting now
- A Study of Mezagitamab in Adults With Kidney Condition Called IgA Nephropathy — Recruiting now
- A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes — Recruiting now
- A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas — Recruiting now
- A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression — Recruiting now
- A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB — Recruiting now
- Exactech Shoulder Post Market Clinical Follow-up Study — Recruiting now
- A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE — Running, not enrolling
- ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation — Completed
- A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) — Completed
- REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels — Running, not enrolling
- Atrasentan in Patients With IgA Nephropathy — Running, not enrolling
- Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN) — Running, not enrolling
- TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations — Running, not enrolling
- A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight — Completed
- A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity — Running, not enrolling
- A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone) — Running, not enrolling
- Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis — Completed
- HbA1c Variation Study — Completed
- IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study) — Stopped early
- A Study of CMV Vaccine (HB-101) in Kidney Transplant Patients — Completed
- Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation — Completed
- Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy — Completed
- Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA) — Completed
- Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2) — Completed
- Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3) — Completed
- TVT Worldwide Registry — Completed